Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy
Year: 2025
Type: article
Study design: Clinical Trial
Source: The Journal of Immunology
Authors: Alison T Stopeck, Maysa Abu-Khalaf, Virginia Borges, Bartosz Chmielowski, Ruta Rao, Bin Xie, Arkadiusz Z Dudek, Lida Mina, Joyce O’Shaughnessy, Michael Chisamore, Paulette Mattson, Michele Gargano, Joanna Cox, Bruno Osterwalder, Jeremy Drees, Ben Harrison, Anissa S H Chan, Xiaohong Qiu, Nadine Ottoson, Nandita Bose, Mark Uhlik, Jeremy Graff, Jose Iglesias
Institutions: Stony Brook University, Thomas Jefferson University, University of Colorado Anschutz, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Rush University Medical Center, Mayo Clinic, Banner MD Anderson Cancer Center, Baylor University Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), HiberCell, Inc. (United States), Zentalis Pharmaceuticals (United States), Abbott (United States), Oakville Public Library
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410207329